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Abstract: Daunorubicin (DNR) has a broad spectrum of anticancer activity, but is limited 
in clinical application due to its serious side effects. The aim of this study was to explore a 
novel “smart” pH-responsive drug delivery system (DDS) based on titanium dioxide (TiO2) 
nanoparticles for its potential in enabling more intelligent controlled release and enhancing 
chemotherapeutic efficiency of DNR. DNR was loaded onto TiO2 nanoparticles by forming 
complexes with transition metal titanium to construct DNR-TiO2 nanocomposites as a DDS. 
DNR was released from the DDS much more rapidly at pH 5.0 and 6.0 than at pH 7.4, which 
is a desirable characteristic for tumor-targeted drug delivery. DNR-TiO2 nanocomposites 
induced remarkable improvement in anticancer activity, as demonstrated by flow cytometry, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and nuclear 4′,6-diamidino-
2-phenylindole staining. Furthermore, the possible signaling pathway was explored by western 
blot. For instance, in human leukemia K562 cells, it was demonstrated that DNR-TiO2 
nanocomposites increase intracellular concentration of DNR and enhance its anticancer efficiency 
by inducing apoptosis in a caspase-dependent manner, indicating that DNR-TiO2 nanocomposites 
could act as an efficient DDS importing DNR into target cancer cells. These findings suggest 
that “smart” DNR delivery strategy is a promising approach to cancer therapy.
Keywords: drug delivery system, daunorubicin, pH-responsive, TiO2 nanoparticles, cancer, 
apoptosis
Introduction
With a broad spectrum of anticancer activity, daunorubicin (DNR) remains the first-
line treatment for hematological malignancies and solid tumors. Unfortunately, its 
therapeutic effect is limited due to its serious side effects, including congestive heart 
failure,1 which presents a challenge for DNR in clinical application. Therefore, efforts 
should be made to develop new delivery techniques that reduce its side effects by 
altering its biodistribution, enhancing its deposition in tumor sites, and improving its 
therapeutic efficacy.
Recently, a so-called “smart” stimuli-sensitive drug delivery system (DDS) that 
responds to certain internal or external stimuli, such as pH, temperature, and magnetism, 
represents a promising approach to improving the efficacy of cancer chemotherapy.2,3 
It is well known that the extracellular pH of tumors is slightly more acidic than that of 
blood and normal tissue. Moreover, numerous pH gradients exist in the intracellular 
endocytic compartment (pH = 4.5–6.5) where cells uptake a DDS via an endocytosis 
process.4 Therefore, an ideal anticancer DDS should retain the drug at pH 7.4 but be 
able to quickly release it at a relatively lower pH (eg, pH 6.0 or 5.0). An important 
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breakthrough in this field is the preparation of a new class 
of nanosized DDS which can be internalized by tumor cells 
through the endocytosis pathway to avoid undesired drug 
release during drug transportation in blood circulation, thus 
improving effective release of the anticancer drug in tumor 
tissue or within tumor cells.5
Furthermore, there has been growing interest in metal 
nanomaterials as anticancer drug carriers recently, which 
represents a promising approach to tumors, although it is 
still under investigation.6,7 Barick et al reported a method for 
entrapping drugs at sites capable of complexing with transition 
metal ions and suggested that drug release is dependent on the 
pH of the medium and nature of the materials which encap-
sulate the drug.7 It is also suggested that this general strategy 
could be readily extended to other inorganic carriers.7
In view of these developments, the aim of this paper was 
to explore a novel “smart” pH-responsive DDS based on 
  titanium dioxide (TiO2) nanoparticles that is chemically stable, 
environmentally friendly, and noncytotoxic.8,9 This DDS 
could provide a simple and easy way to enable intelligently 
controlled release of DNR and enhance its chemotherapeutic 
efficiency. To the best of the authors’ knowledge, no study has 
been carried out on TiO2 nanoparticles for “smart” stimuli-
sensitive DDS and is investigated here for the first time. In 
this study, DNR was loaded on TiO2 nanoparticles to construct 
DNR-TiO2 nanocomposites as a DDS. Loading efficiency and 
influence of pH value on drug release behavior of the DDS 
were investigated by high-performance liquid chromatogra-
phy. Additionally, tumor cellular uptake and cytotoxicity of 
the DDS were evaluated in K562 leukemia cells.
Materials and methods
Chemicals and apparatus
DNR was purchased from Pharmacia Italia SpA (Nerviano, 
Italy), and its stock solution was freshly prepared and stored 
in the dark at 4°C. Phosphate buffer solution (PBS) with dif-
ferent pH value (pH 7.4, 6.0, 5.0) was prepared with double 
distilled water. TiO2 nanoparticles (P25; Evonik Industries 
AG, Essen, Germany) were suspended in sterilized PBS. 
Caspase 3 antibody, β-actin antibody, and horseradish perox-
idase-conjugated immunoglobulin G antibody were obtained 
from Nanjing KeyGen Biotech Co, Ltd, (Nanjing, China). 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and 4,6-Diamidino-2-phenylindole (DAPI) were 
obtained from Sigma-Aldrich Corporation (St Louis, MO) and 
stored in the dark. All other reagents were of analytical grades. 
The images of transmission electron microscope, electron 
diffraction, and high-resolution transmission electron 
microscope were obtained by a JEM-2100 transmission 
electron microscope (JEOL Ltd, Tokyo, Japan). Fluorescent 
microscopic images were shot on an Olympus IX51 inverted 
microscope (Olympus Corporation, Tokyo, Japan). Optical 
density at 492 nm was recorded by multiwell spectrophotom-
eter reader (MK3; Thermo Labsystems, Vantaa, Finland).
Construction of DNR-TiO2 
nanocomposites
For a typical drug loading experiment, 2 mL aqueous solution 
of DNR (2 mg/mL) was added to 1 mL aqueous suspen-
sion of TiO2 nanoparticles (10 mg/mL). The above reaction 
mixture was continuously agitated with a stirrer at 50 g and 
kept overnight in the dark to construct nanocomposites of 
DNR-loaded TiO2 nanoparticles which acted as the DDS. 
DNR-loaded TiO2 nanoparticles were separated from the 
free-standing drug molecules through centrifugation at 
5000 g for 20 minutes and the supernatant was determined 
by high-performance liquid chromatography, allowing 
estimation of drug encapsulation efficiency and loading 
efficiency. Encapsulation efficiency and loading efficiency 
were calculated by the following equations:
Encapsulation efficiency (%) = (Amount of drug in  
  DNR-TiO2 nanocomposites/initial amount of drug) × 100
Loading efficiency (%) = (Amount of drug in DNR-TiO2  
  nanocomposites/amount of DNR-TiO2 nanocomposites)  
  × 100
Drug release
Release behavior of DNR from DNR-TiO2 nanocomposites 
was investigated at pH 5.0 (approximate pH in endosomes or 
lysosomes), pH 6.0 (pH of the environment around the tumor), 
and pH 7.4 (pH of physiological blood). DNR-loaded TiO2 
nanoparticles (20 mg) were dispersed in PBS (pH 7.4, 5 mL) 
and transferred into a dialysis bag (Spectra/Por®; Spectrum 
  Laboratories, Inc, Rancho Dominguez, CA). The dialysis bag 
was then immersed in 95 mL PBS at pH 5.0, 6.0, or 7.4. The 
release medium was continuously agitated with a stirrer at 
50 g and 37°C. At predetermined time intervals, 2 mL of the 
external medium was collected and replaced with the same 
fresh PBS. The amount of released DNR in the medium was 
then determined by high-performance liquid chromatography 
(LC-310; Skyray Instrument, Nanjing, China).
Cell culture
K562 leukemia cells were obtained from Institute of Hema-
tology, Chinese Academy of Medical Sciences (Beijing, China) 
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and cultured in Gibco® Roswell Park Memorial   Institute 
1640 medium (Life Technologies, Grand Island, NY) 
supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma-Aldrich), 100 U/mL penicillin (Sigma-Aldrich), 
and 100 µg/mL streptomycin (Sigma-Aldrich) at 37.0°C in 
humidified air with 5% carbon dioxide. Cells were in log 
phase prior to the following experiments to minimize experi-
mental variations which occur with proliferative status.
Cell internalization studies
Cells (1 × 105/mL) were seeded in six-well culture plates and 
grown overnight. They were then treated with either DNR or 
DNR-TiO2 nanocomposites (DNR concentration 0.5 µg/mL) for 
6 hours. To visualize the cellular uptake of DNR with different 
treatments, the cells were examined by fluorescent microscopy 
(λex 488 nm, λem 515 nm) after incubation for 6 hours. Further-
more, the cells were resuspended in PBS after being washed 
three times. DNR uptake was analyzed by FACSCalibur™ 
flow cytometer (BD Biosciences, San Jose, CA); the gate was 
arbitrarily set for the detection of green fluorescent DNR.
Assay of anticancer activity
Cytotoxicity of TiO2 nanoparticles, DNR, and DNR-TiO2 
nanocomposites was studied in leukemia K562 cells with 
MTT assays. Cells (1 × 105/mL) were seeded in 96-well 
plates and incubated for 24 hours. Growth medium was then 
replaced with 200 µL of the preprepared medium contain-
ing either free DNR or DNR-TiO2 nanocomposites (DNR 
concentration 0, 0.125, 0.25, 0.5, and 1 µg/mL). Cells were 
treated by TiO2 nanoparticles alone as well to evaluate its 
cytotoxicity. Cells without any treatment were used as the 
control group. Cells were further incubated for 48 hours, and 
relative anticancer activity was assessed with MTT assays. 
After 48 hours, MTT assay was carried out. In brief, MTT 
solutions were added after treatment and incubated for an 
additional 4 hours. Dimethyl sulfoxide (Sinopharm Chemical 
Reagent Co Ltd, Shanghai, China) was added to solubilize the 
formazan crystal, and optical density 492 nm was recorded. 
Cell viability (%) was calculated as follows:
Optical density492 nm in test cells/Optical density492 nm in control cells × 100
DAPI staining
Cells were treated with the above methods for 48 hours, 
and were then fixed with 4% polyoxymethylene prior to 
washing with PBS. The washed cells were then stained with 
1 mg/mL DAPI for 15 minutes in the dark. Staining images 
were recorded with fluorescent microscope.
Western blot analysis
After the different treatments, caspase 3 expression was 
detected by western blot. In brief, total protein was isolated, 
subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, and transferred to a polyvinylidene fluoride 
membrane. After being blocked, the membrane was incubated 
with primary polyclonal antibodies either anti-caspase 3 or 
anti-β-actin overnight at 4°C, and subsequently incubated 
with horseradish peroxidase-conjugated immunoglobulin G 
antibody as the secondary antibody for 1 hour at room tem-
perature. The protein bands were detected by an enhanced 
electrochemiluminescence detection system (ECL system, 
Amersham, UK). After normalization by corresponding 
β-actin expression, protein expression levels of caspase 3 
were determined by densitometry scans.
Statistical analysis
All data are presented as mean ± standard deviation. F-test was 
used for significance testing, and P , 0.05 was considered 
to be statistically significant. All tests were performed using 
IBM SPSS software (v 13.0; SPSS Inc, Chicago, IL).
Results and discussion
Characterization of TiO2 nanoparticles
Transmission electron microscopic images of TiO2 nanopar-
ticles are shown in Figure 1. Observed TiO2 nanoparticles had 
a spherical shape with a diameter of about 25 nm   (Figure 1A). 
The particles had dimensions suitable for escaping rapid renal 
excretion, as well as avoiding components of the reticular 
endothelial system. Thus, potentially passive targeting of 
drugs to tumors was facilitated via enhanced permeation 
and retention effect, and drug accumulation in tumor 
cells after endocytosis was increased.4 Also, the selected-
area electron diffraction (Figure 1B) patterns confirmed 
that TiO2 nanoparticles were single crystalline with a 
Figure  1  Transmission  electron  microscopic  image  (A),  electron  diffraction 
patterns (B), and high-resolution transmission electron microscopic image (C) of 
titanium dioxide nanoparticles.
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    hexagonal-wurtzite structure. The fine microstructures of TiO2 
nanoparticles were further characterized by high-resolution 
transmission electron microscope (Figure 1C), which showed 
that TiO2 nanoparticles were highly crystalline.
DNR-TiO2 nanocomposites as a DDS
A previous study showed that the analog of DNR, doxo-
rubicin, has three potential metal binding sites.7 One is the 
nitrogen atom in the sugar moiety and the other two are the 
chelating sites of quinone and phenolic oxygens on both sides 
of the anthracycline aromatic moiety.7 In the present study, 
the capacity of TiO2 nanoparticles as a drug carrier for load-
ing DNR was explored. Color change of pure DNR from red 
to orange was observed during the loading process, indicat-
ing that DNR molecules could form complexes with TiO2 
nanoparticles. The more likely metal binding sites of DNR 
were deduced to be the two keto-phenolate functions: C=O 
and C–O− (six-membered chelate), due to the low affinity of 
metal ions for the nitrogen atom donor. In addition, DNR, 
which is positively charged, can be easily self-assembled 
onto the surface of TiO2 nanoparticles through electrostatic 
interaction as the relative surface of TiO2 nanoparticles is 
negatively charged in pH 7.4 aqueous solutions.8,10 Thus, the 
authors believe that DNR was absorbed onto the TiO2 nano-
particles by forming complexes with transition metal titanium 
and by electrostatic interaction. Figure 2 shows a proposed 
schematic representation of DNR loading onto TiO2 nanopar-
ticles through the formation of DNR-TiO2 nanocomposites 
as a DDS. Encapsulation efficiency and loading efficiency 
of DNR-loaded TiO2 nanoparticles were assessed and calcu-
lated as 65.46% ± 6.82% and 20.63% ± 3.55%, respectively. 
Results show that DNR-loaded TiO2 nanoparticles may 
efficiently act as anticancer drug delivery carrier.
pH-triggered drug release behavior
As shown in Figure 3, release of drug molecules depended 
on pH of the medium and release time. Drug release at 
pH 7.4 was slow and sustained, with release ratio at about 
18% within 48 hours. However, at lower pH, DNR release rate 
was much faster, with approximately 67% (pH 6.0) and 86% 
(pH 5.0) of the drug released within 48 hours.   Protonation 
of the drug (dissociation of DNR-TiO2   nanocomposites) 
occurred at lower pH, which released chemisorbed drug 
molecules into the medium. Furthermore, surface charges of 
TiO2 nanoparticles turned positive at lower pH, which blunted 
the electrostatic interaction of DNR and TiO2 nanoparticles 
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Figure 2 Schematic representation and photographic image (inset) of daunorubicin loading onto titanium dioxide nanoparticles through the formation of daunorubicin-
titanium dioxide nanocomposites.
Abbreviations: DNR, daunorubicin; Nps, nanoparticles; TiO2, titanium dioxide.
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and facilitated the drug release process. These results dem-
onstrate pH-triggered drug release behavior from the novel 
DDS, which is of particular interest. It may be hypothesized 
that most DNR will remain in the carrier for a considerable 
time period at normal physiological conditions (pH 7.4), 
indicating the potential for prolonged DNR retention time 
in blood circulation and thereby greatly reducing the side 
effects to normal tissues. On the other hand, once DNR-
loaded TiO2 nanoparticles are taken up by tumor cells via 
endocytotic process, a faster release may occur at lower local 
pH, ie, surrounding the tumor site or inside the endosome and 
lysosome of tumor cells, leading to significant improvement 
in cancer treatment efficacy.
Cellular uptake
Fluorescent DNR allows facile observation of the cellular 
uptake of free DNR and DNR-loaded TiO2 nanoparticles 
by K562 cells, quantitatively detected by flow cytometry 
without additional markers. Figure 4A illustrates the typi-
cal results of fluorescent microscopy of intracellular DNR. 
The internalization of DNR loaded onto TiO2 nanoparticles 
(Figure 4A, right panel) was much higher after 6 hours 
of incubation compared with the free DNR (Figure 4A, 
left panel), resulting in stronger fluorescence intensity in 
K562 cells. The relative intracellular fluorescence intensity 
of DNR analyzed by flow cytometry allows quantitative 
comparison of the cases mentioned above (Figure 4B). 
Intracellular fluorescence intensity for the group of DNR-
TiO2 nanocomposites produced 65% ± 3.7% enhancements 
compared to the group of free DNR. These results clearly 
show that DNR-TiO2 nanocomposites as a DDS increased 
pH = 5.0
pH = 6.0
pH = 7.4
+ H+
– H+
TiO2 + DNR DNR-TiO2
0
0
20
40
60
80
100
48 12 16 20 24 28 32 36 40 44 48
Time (hours)
C
u
m
u
l
a
t
i
v
e
 
r
e
l
e
a
s
e
 
(
%
)
Figure 3 In vitro daunorubicin release behavior at pH 7.4, 6.0, and 5.0.
Abbreviations:  DNR,  daunorubicin;  DNR-TiO2,  daunorubicin-titanium  dioxide 
nanocomposites; TiO2, titanium dioxide.
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Figure  4  Fluorescent  microscopic  images  of  K562  cells  (A)  treated  with  free 
daunorubicin (left panel) and titanium dioxide nanoparticles loading daunorubicin 
as  a  drug  delivery  system  (right  panel).  Comparison  of  the  respective  average 
intracellular fluorescence intensity is also shown (B). Concentrations of daunorubicin 
and titanium dioxide nanoparticles are 0.5 µg/mL and 10 µg/mL, respectively.
Note: Data expressed as mean ± standard deviation (n = 3).
Abbreviations: DNR, daunorubicin; Nps, nanoparticles; TiO2, titanium dioxide.
the cellular uptake of DNR substantially. TiO2 nanoparticles 
demonstrated significant properties of a drug carrier, which 
represents a promising approach to cancer therapy.
Anticancer activity in vitro
A common characteristic of a nanoparticle-based DDS is the 
rapid internalization and intracellular localization into acidic 
endosomes and/or lysosomes of cells.11,12 Due to this common 
pathway of cellular uptake, there has been significant interest 
in methods to engineer acid-triggered responses from DDS 
for rapid intracellular release of therapeutics.13 To further 
explore the anticancer efficiency of the novel pH-responsive 
DDS based on TiO2 nanoparticles for DNR, K562 cells were 
cultured with free DNR at different concentrations (0, 0.125, 
0.25, 0.5, and 1 µg/mL) and DNR-TiO2 nanocomposites with 
equivalent DNR concentration for 48 hours. Cytotoxicity 
results were estimated by MTT assay (Figure 5).
A cytotoxicity test of the nanomaterial is the first-level 
evaluation before its biomedical applications. When treated by 
TiO2 nanoparticles, about 95% of the cells survived   (Figure 5, 
blue line), which is consistent with a previous report.10 The 
lack of cytotoxicity of TiO2 nanoparticles thus ensures a wide 
potential range of applications in the field of   biomedical 
science and cancer therapy. Compared with DNR alone 
 ( Figure 5, green line), viability of K562 cells treated by DNR-
TiO2 nanocomposites obviously decreases   (Figure 5, black 
line). Results also indicate that with   increasing   concentrations 
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of DNR, lethality increased, suggesting a dose-dependent 
effect in vitro. Increased cytotoxicity may be due to improved 
DNR cellular uptake by DNR-TiO2 nanocomposites (as illus-
trated above) and to the induced release of DNR from TiO2.
The process of controlled release is of particular interest 
in achieving DNR delivery with TiO2. At normal physi-
ological conditions (pH 7.4), it is expected that most DNR 
conjugated with TiO2 will remain in the carrier for a con-
siderable time period. As well documented, a nanoparticle-
based DDS could be internalized through the endocytosis 
pathway.14 In the endocytic compartment, pH values range 
4.5–6.5;15 and at this low pH, protonation of the drug occurs. 
Protonation will then trigger the release of chemisorbed drug 
molecules and turn surface charges of TiO2 nanoparticles to 
positive, blunting the electrostatic interaction of DNR and 
TiO2 nanoparticles which facilitates the drug release process. 
Consequently, a faster release of DNR from DNR-TiO2 
nanocomposites occurs once the carrier is taken up by the 
tumor cells via endocytic process. Therefore, a sufficiently 
high concentration of DNR can be generated within a rea-
sonably short period of time, thereby greatly promoting the 
cell-killing effects efficiently. Considering that a high dose 
of DNR may lead to serious side effects, especially conges-
tive heart failure,1 DNR-TiO2 nanocomposites as a DDS 
improves therapeutic efficacy without a high usage of DNR, 
thus potentially minimizing its toxic side effects.
As shown in the inset of Figure 5, optical microscopic 
observations confirm MTT assay results. K562 cells 
without any treatment attached to the plate with normal 
spherical shape (Figure 5A). Notably, cells treated with TiO2 
  nanoparticles had no morphological changes (Figure 5B). It 
is obvious that DNR (Figure 5C) and the even more effective 
DNR-TiO2 nanocomposites (Figure 5D) could kill more can-
cer cells and cause more significant morphological changes, 
indicating an increased probability in cell death.
Morphologic characterization  
of apoptosis
To explore the mechanism of distinct improvement in antican-
cer activity induced by the novel pH-responsive DDS, nuclear 
DAPI staining was performed. To confirm the   existence of 
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Figure  5  Cytotoxic  effect  of  daunorubicin  or  daunorubicin-titanium  dioxide 
nanocomposites on K562 leukemia cells. Microscopic images of K562 cells after 
different treatments for 48 hours are shown inset: (A) untreated cells as control, 
(B) titanium dioxide nanoparticles, (C) daunorubicin alone, and (D) daunorubicin-
titanium  dioxide  nanocomposites.  Concentrations  of  daunorubicin  and  titanium 
dioxide nanoparticles are 1 µmol/L and 10 µg/mL, respectively.
Note: Data expressed as mean ± standard deviation (n = 3).
Abbreviations:  DNR,  daunorubicin;  DNR-TiO2,  daunorubicin-titanium  dioxide 
nanocomposites; Nps, nanoparticles; TiO2, titanium dioxide.
A B
C D
Figure 6 Nuclear morphologic changes of K562 leukemia cells after different treatments for 48 hours: (A) untreated cells as control, (B) titanium dioxide nanoparticles, 
(C) daunorubicin alone, and (D) daunorubicin-titanium dioxide nanocomposites. Concentrations of daunorubicin and titanium dioxide nanoparticles are 0.5 µg/mL and 
10 µg/mL, respectively.
Notes: Magnification: ×400. Arrows indicate cells with apoptotic nuclear condensation and fragmentation.
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apoptosis, morphological changes of the cells were studied. 
Evaluation of normal or apoptotic cells depends on morpho-
logical characterization. Normal nuclei (smooth nuclear) and 
apoptotic nuclei (condensed or fragmented chromatin) were 
easily distinguished. As shown in Figure 6, nuclear   morphology 
analysis showed characteristic apoptotic changes, such as chro-
matin condensation, convoluted nuclei with   cavitations, frag-
mentation of the nucleus, and apoptotic bodies in K562 cells 
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Figure 7 Expression of caspase 3 in K562 cells by western blotting analysis. After 
normalization by corresponding β-actin expression, protein expression levels of 
caspase 3 were determined by densitometry scans to obtain quantitative data.
Note: Data expressed as mean ± standard deviation (n = 3).
Abbreviations:  DNR,  daunorubicin;  DNR-TiO2,  daunorubicin-titanium  dioxide 
nanocomposites; Nps, nanoparticles; TiO2, titanium dioxide.
after treatment with DNR and DNR-TiO2 nanocomposites. 
There was almost no apoptotic evidence in the control group 
(Figure 6A) and TiO2 group (Figure 6B). When cells were 
treated with DNR-TiO2 nanocomposites   (Figure 6D), typical 
apoptotic morphology was more apparent than that of cells 
treated with DNR alone (Figure 6C). These findings strongly 
indicate that DNR-TiO2 nanocomposites killed the cancer cells 
by inducing apoptosis rather than necrosis.
Caspase 3 activity during  
induced apoptosis
Nuclear DNA is the main subcellular site of DNR action for its 
anticancer activity. DNR can efficiently accumulate in nucleus, 
intercalate DNA, and act as a cytostatic and apoptotic agent 
against tumor cells. To explore the possible signaling pathways 
through which DNR-TiO2 nanocomposites induced distinct 
improvement in anticancer activity, the changes in expres-
sion levels of the apoptosis-regulating protein, caspase 3, 
were examined by western blot. As shown in Figure 7, when 
K562 cells were treated with DNR and DNR-TiO2 nanocom-
posites for 48 hours, levels of caspase 3 protein were signifi-
cantly upregulated compared to control group.   Meanwhile, 
the upregulated levels of caspase 3 protein in DNR-TiO2 
nanocomposites group were slightly higher than those in DNR 
group (P , 0.05). However, the caspase 3   protein was not 
obviously altered when the cells were treated with TiO2 nano-
particles (P . 0.05). Caspase activation is generally considered 
DNR
DNR-TiO2nanocomposites
Uptake
Endosome
pH-triggered drug release
Caspase 3
DNA damage
Apoptosis
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Figure 8 Schematic illustration of the possible process of distinct improvement in anticancer activity by the novel pH-responsive drug delivery system based on titanium 
dioxide nanoparticles for daunorubicin.
Abbreviations: DNR, daunorubicin; Nps, nanoparticles; DNR-TiO2, daunorubicin-titanium dioxide nanocomposites; TiO2, titanium dioxide.
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to be a key hallmark of apoptosis, and caspase 3 is the main 
effector caspase that is involved in apoptosis.16 These results 
indicate that the studied DDS induces distinct improvement in 
anticancer activity in a caspase-dependent manner.
Based on the above studies, Figure 8 schematically illus-
trates the possible processes that lead to the distinct improve-
ment in anticancer activity. DNR can be easily self-assembled 
onto the surface of TiO2 nanoparticles by forming complexes 
with transition metal titanium to construct DNR-TiO2 nano-
composites as a DDS. Drug release shows strong dependence 
on pH value, which is higher at lower pH. Thereby, TiO2 
nanoparticles load an amount of DNR molecules and carry 
them into cells, increasing intracellular concentration of DNR 
dramatically, and thus enhancing the suppression of cancer cell 
proliferation. The therapeutic concentration inside cancer cells 
is increased, which enhances the efficiency of drugs per dosage 
and, accordingly, solves some of the limitations of anticancer 
drugs, thereby exhibiting tremendous application potential in 
cancer therapy. Finally, apoptosis, a preferred mode of kill-
ing cancer cells in cancer therapy, is induced synergistically, 
resulting in a distinct improvement in anticancer activity.
Conclusion
In the present study, a pH-responsive nanocomposite com-
posed of self-assembled DNR and TiO2 nanoparticles was 
developed for a “smart” stimuli-sensitive DDS. Drug release 
from the DDS was significantly accelerated by decreasing pH 
from 7.4 to 5.0, which is of particular interest to cancer therapy 
due to the acidic extracellular tumor environment and intracel-
lular endosomal and/or lysosomal compartments. DNR-TiO2 
nanocomposites increased the accumulation of DNR in tumor 
cells and induced caspase-dependent apoptosis, enhancing 
anticancer activity and potentially minimizing the toxic side 
effects of DNR. All these characteristics demonstrate that the 
novel pH-responsive DDS based on TiO2 nanoparticles for 
DNR is a promising strategy for clinical practice.
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